New antiviral drug to go into production in Urals

Print 14 October 2014
MARCHMONT Innovation News

A new antiviral drug called “Triasavirin” is expected to soon be put into production in the Urals; the biotech solution is believed to be based on an innovative technology of directly impacting a virus, the Skolkovo Foundation website reported . The Ural Center for Biopharma Technologies (UCBT), the developer of the solution, is a Skolkovo resident. 

“Triasavirin” is reported to have been fine-tuned, tested and even approved by the Russian Ministry of Healthcare and is now a registered medicine in Russia. 

“The “Triasaverin” molecule is focused directly on a virus. We unleash it to ‘deceive’ the root cause of the virus by ‘offering’ the intruder a flawed construction material, thus inhibiting its replication process. When the virus runs into the molecule, it absorbs it and loses its ability to multiply as a result,” said Gelena Lifshits, the head of biomed programs at Skolkovo. 

According to Ms. Lifshits, UCBT appears to have proven the efficacy of the new drug in fighting “practically all known strains of flu and tick-borne encephalitis.” The developer continues research into its possible use against other viruses, including the ones responsible for the entire group of upper respiratory tract infections, she added.

Return